Last reviewed · How we verify
Victoza (liraglutide)
Victoza activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.
Victoza activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. Used for Type 2 diabetes mellitus, Weight management in obese or overweight patients (at higher doses as Saxenda).
At a glance
| Generic name | Victoza (liraglutide) |
|---|---|
| Also known as | Victoza |
| Sponsor | Zealand University Hospital |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural hormone GLP-1. It binds to GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite. This results in improved glycemic control and modest weight loss in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
- Weight management in obese or overweight patients (at higher doses as Saxenda)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Hypoglycemia (when combined with insulin or sulfonylureas)
Key clinical trials
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction (NA)
- RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. (PHASE4)
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (PHASE3)
- Effects of GH and Lirglutide on AgRP (PHASE4)
- Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Victoza (liraglutide) CI brief — competitive landscape report
- Victoza (liraglutide) updates RSS · CI watch RSS
- Zealand University Hospital portfolio CI